Kornimate/medical-research-clean huggingface dataset:
imaging-based, non-invasive diagnosis of persistent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the main objective of the present project is to develop an imaging-based tool to determine the origin and cause of persistent atrial fibrillation (af). the result of the study is a diagnostic method which aids the medical work-up of patients suffering from this disease.

atrial fibrillation (af) is the most common arrhythmia associated with substantial morbidity and mortality in humans. histopathological studies of persistent af have reported extracellular matrix remodeling with fibrotic infiltration which may cause atrial dilation. the degree of the fibrosis might have a significant impact on wave propagation during af. the main objective of the present project is to develop an imaging-based tool to determine the origin and cause of persistent af. the obtained clinical parameters of patients and controls (electrocardiography, ecocardiography and mr imaging data) will be correlated with known markers in order to identify novel markers for af diagnosis.

Eligibility criteria:
inclusion criteria: * age: 20-80 years * weight: 50-120 kg * persistent, permanent or paroxysmal atrial fibrillation * clinically stable patients: outside of an acute cardiac event with constant chronic medication * optimum echographic window exclusion criteria: * patients with: rheumatic mitral disease; acute myocardial-pericarditis; chronic rheumatism, under chronic or immunomodulatory treatment; infectious-inflammatory process of any cause * patients undergoing oncology treatment * patients under medication in another study * patients undergoing immunosuppressive therapy * contraindication for magnetic resonance imaging (mri) * patients with valvular prosthesis, pacemaker of any type, metallic elements in the body (including metal particles accidentally in the body or as a result of exercising certain professions); pregnant patients; patients with known poly-allergy; patients with altered renal function (creatinine clearance \<40 ml/min determined by the cockcroft-gault formula).
organosilane for surface cleaning in intensive care units

Conditions: Infection, Hospital

Summary: the purpose of this study is to evaluate if surface disinfection with organosilane associated with traditional cleaning reduces the incidence of healthcare-associated infections (hais) in intensive care units when compared with traditional cleaning alone.


Eligibility criteria:
inclusion criteria: * all patients aged 18 years and older who will be admitted to the participating icus exclusion criteria: * patients under 18 years * icus that may use any organosilane formulation for surface disinfection

Keywords: infection control infections intensive care units pneumonia, ventilator associated catheter-related infections urinary tract infections organosilanes costs and cost analyses
the impact of dose of angiotensin-receptor blocker valsartan and genetic polymorphism on the post-mi ventricular remodeling

Conditions: Myocardial Infarction

Summary: angiotensin-converting enzyme inhibitors and angiotensin-receptor blocker valsartan ameliorate ventricular remodeling after myocardial infarction (mi). although the amount of those drugs used in previous clinical trials, therefore recommended in practical guidelines is maximum clinical dose, it has not been clearly demonstrated whether the recommended dose is more efficacious compared to lower dose commonly used in clinical practice. in addition, the impact of genetic polymorphism in neurohormonal system on the pharmacological effect has not been explored in the setting of post-mi remodeling. therefore, the investigators evaluate whether submaximal dose, which are lower than those in major pivotal trials but typically used in clinical practice, can offer similar benefit in post-mi ventricular remodeling.

a total of 1116 patients with left ventricular (lv) dysfunction following the first episode of acute st-elevation mi are to be enrolled and randomized to maximal tolerable dose (up to 320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2:1 ratio. echocardiographic analysis for quantifying post-mi ventricular remodeling and genotyping of blood samples are conducted in central core laboratory. clinical assessment and laboratory test are performed at fixed times, and genetic polymorphisms of the patients are tested at the time of admission.

Eligibility criteria:
inclusion criteria: * both gender * age \> 18 * first episode of acute st-elevation mi * an echocardiographic left ventricular ejection fraction less than 50 % * patients who provide written informed consent exclusion criteria: * contraindications for use of angiotensin receptor blockers (arbs)(hypersensitivity, pregnancy, bilateral renal artery stenosis) * urgent need for revascularization procedure * severe heart failure (need for intravenous inotropic support) * persistent (\> 1 hour) severe hypotension (systolic blood pressure \< 90 mmhg) * refractory or potentially lethal arrhythmias * hemodynamically significant right ventricular infarction * primary valvular diseases * congenital heart disease * idiopathic hypertrophic cardiomyopathy * concomitant inflammatory cardiopathy * significant hepatic dysfunction * significant renal dysfunction * anemia (hemoglobin \< 10 mg/ml) * psychiatric disorders, alcohol or durg abuse * any concomitant disease that might interfere with drug evaluation (especially if life expectancy is less than 1 year) * participation in any other pharmacological study within 2 months * refusal or inability to provide informed consent

Keywords: post myocardial infarction ventricular remodeling valsartan
her2-positive locally advanced/metastatic gastric and/or gastroesophageal junction (gej) adenocarcinoma in russia

Conditions: Adenocarcinoma

Summary: this study is a multicenter non-interventional observational retrospective study with secondary data collection

it will be multicenter study. planned number of study sites is about 50 oncological centers specialized on anticancer chemotherapy in various regions of russia. a multi-center collaborative effort will help to describe characteristics of patients with her2-positive gastric and/or gej adenocarcinoma in different regions in the most comprehensive way and to capture more patients into database, not only limited to a single institution

Eligibility criteria:
inclusion criteria: * patients with locally advanced/metastatic gastric and/or gastroesophageal junction (gej) adenocarcinoma, with the diagnosis established between the 1st january 2022 and the 1st january 2023. * patients with documented her2+ status based on ihc score ± ish status. * patients have an adequate archival tumor sample and slides suitable for reassessment her2 status by the reference laboratory. * age ≥ 18 years at the time of inclusion. * patients provided written consent allowing for data and samples to be used in the future and this study would be covered by the consent for future use in accordance with ich gcp, gpp (good pharmacoepidemiology practices) and local law prior to inclusion in the study. if the patient is deceased, a waiver may be accepted. exclusion criteria: * patients receiving trastuzumab deruxtecan currently or in the anamnesis. * the participation in any randomized controlled trial within period since diagnosis (between the 1st january 2022 and the 1st january 2023) until the timepoint of data collection
pap smear research study

Conditions: Cervical Cancer

Summary: the principal hypothesis of this study is that hpv testing and/or p16 testing, either alone or in combination or associated with a pap smear, will demonstrate greater specificity for clinically significant precancerous disease than will a pap smear alone and that these tests will be of comparable or superior sensitivity than the pap smear.


Eligibility criteria:
inclusion criteria: * 18 years and older * ability to speak and clearly understand english * female patients exclusion criteria: * no previous history of cervical cancer treatment(leep,laser,cone etc.) * women who have had pap smears within the previous 10 months * women under the age of 18. * women who are pregnant. * inability to give informed consent in english

Keywords: pap test hpv healthy patients screened for cervical cancer tests.
efficacy and mechanism of action of scig in patients with stiff person syndrome (sps)

Conditions: Stiff-Person Syndrome

Summary: this is a pilot, proof-of concept investigator-initiated trial planned for 22 patients with the diagnosis of stiff person syndrome (sps). the study will compare efficacy of treatment using subcutaneous immunoglobulin therapy (scig) compared to intravenous immunoglobulin (ivig) therapy. the majority of ivig naïve subjects (those not already receiving ivig) are typically managed with non-immunotherapy mostly gamma aminobutyric acid (gaba) -enhancing drugs such as baclofen or diazepam.

study design:this is a proof of concept observational prospective, open label, study on the safety, efficacy and convenience of treatment with scig study of 22 patients at thomas jefferson university hospital. two cohorts of patients within the total of 22 will be included; half of them (11 patients) currently receiving and responding to ivig and the other half starting de novo on scig. patients diagnosed with sps according to defined sets of symptoms will be eligible to enroll. the primary clinical outcome will be based on clinical efficacy measures, as used before for the ivig trial, based on changes in the stiffness index and heightened sensitivity scores, using the validated scales that the investigators have had previously utilized and validated (dalakas et al 2001; see attached at the end of the protocol). these same measurements will be applied while on ivig (weeks 0, 4, 8, 12) and will be compared to the measurements obtained during scig (weeks 16, 20, 24, 28). the secondary outcome will be quality of life (qol) responses and patient preference for each treatment.

Eligibility criteria:
inclusion criteria: * men or women aged \>18 years * diagnosis of sps based on standard criteria * ivig group: receiving the equivalent of 1-2 g/kg ivig every 4 weeks with dependence\* on ivig to maintain clinical response \*dependence is clinically determined either by symptomatic worsening of condition at the end of the inter-dose interval or by worsening after dose reduction or discontinuation within the previous 3 months. * ivig-naïve group: patients with symptomatic sps and never treated with ivig (ivig-naïve group), poorly controlled with standard therapy exclusion criteria: * pregnancy, planned pregnancy, breast-feeding or unwillingness to practice contraception * severe concurrent medical conditions, which would prevent treatment or assessment, including significant hematological, renal or liver dysfunction or malignancies * initiation of immunomodulatory treatment other than ivig in the past 3 months * participation in a trial of an investigational medicinal product in the past 12 weeks * presence of any medical condition, which in the opinion of the investigator might interfere with performance or interpretation of this study.
cardiac septal hypertrophy in the fetus of diabetic mother and its effect on postnatal cardiac function

Conditions: Cardiology in Fetus of Diabetic Mother

Summary: good glycemic control is superior to poor glycemic control in reducing risk of interventricular septum thickness among fetuses of diabetic mothers

good glycemic control is superior to poor glycemic control in reducing risk of interventricular septum thickness among fetuses of diabetic mothers specially during third trimester of pregnancy

Eligibility criteria:
inclusion criteria: * singleton pregnancy * gestational age 36 weeks exclusion criteria: * congenital anomalies * obstetric complications * medical disorders other than diabetes

Keywords: cardiology fetus of diabetic mother
pharmacokinetics of ceftaroline in subjects 12 to 17 years of age

Conditions: Infection

Summary: the purpose of this study is to determine the pharmacokinetics of ceftaroline in pediatric subjects

the purpose of this study is to determine the pharmacokinetics profile of ceftaroline in pediatric subjects

Eligibility criteria:
inclusion criteria: * hospitalized and receiving antibiotic therapy for treatment of a suspected infection of any type * body mass index (weight \[kg\]/height squared \[m2\]) of no more than 30 * males and females between 12 and 17 years of age, inclusive exclusion criteria: * history of any hypersensitivity or allergic reaction to any β-lactam antimicrobial * past or current history of epilepsy or seizure disorder * critically ill or unstable patients

Keywords: pk pharmacokinetics
peppermint inhalation versus swedish massage on chemotherapy induced-nausea and vomiting in children with leukemia

Conditions: Leukemia

Summary: clinical trials was used to compare the effect of peppermint inhalation and swedish massage on chemotherapy induced-nausea and vomiting in children with leukemia. the main research hypotheses are: * children with leukemia who receive peppermint inhalation exhibit less chemotherapy induced- nausea and vomiting than those who don't receive. * children with leukemia who receive swedish massage exhibit less chemotherapy induced-nausea and vomiting than those who don't receive. * children with leukemia who receive swedish massage exhibit less chemotherapy induced- nausea and vomiting than those who receive peppermint inhalation. children divided into three groups of study ( control group, peppermint inhalation group and swedish massage group) to identify its effect on chemotherapy induced nausea and vomiting.


Eligibility criteria:
inclusion criteria: * received first chemotherapy session * intact skin in the massage exclusion criteria: * chronic and acute disorders such as respiratory, cardiovascular diseases...etc. * allergy from any essential oils.

Keywords: leukemia swedish massage peppermint inhalation nausea vomiting chemotherapy children
spinal manipulation with laser therapy versus dry needling in chronic lower backache

Conditions: Low Back Pain

Summary: to determine the effectiveness of spinal manipulation with laser therapy versus dry needling for pain, disability and fear of movement in chronic low backache


Eligibility criteria:
inclusion criteria: * those patients will be included in the study who have chronic low back pain (12 week duration). both genders aged 18-60 years low back pain exclusion criteria: * those patients will be excluded in the study who have needle phobia, any infection, cancer, dermal changings, heart transplant, pregnancy, rheumatic fever(25)fracture, cauda equina syndrome, arrhythmia, sensory deficiency, mental illness, surgery, osteoporosis, low term use of steroid
ed observation for opioid use disorder

Conditions: Opiod Use Disorder

Summary: this is a multicenter, randomized clinical comparative effectiveness trial (rct) in which patients with untreated oud presenting to a northwell health emergency department (ed), nyulh-brooklyn, nyulh-tisch, and bellevue hospital will be randomized (1:1) to be managed clinically through either a standard ed visit or an extended visit through ed observation (edou).

in this hybrid implementation-effectiveness study, there is no direct research intervention. rather, clinical care with well-documented effectiveness will be delivered at the discretion of clinical staff guided by clinical protocols for the management of oud with moud (medications for opioid use disorder) introduced at each site prior to study enrollment. enrolled patients will be randomized to ed vs. edou and to participate in assessments conducted at the index visit and at 30 days and 90 days. patient level data will also be matched with medicaid claims data for more robust analyses and to support the development of clinical quality measures.

Eligibility criteria:
inclusion criteria: * is 18 years of age or older * is able to speak english sufficiently to understand study procedures * has a history of non-medical opioid use * is a potential candidate for ed-based moud treatment initiation and referral at the site as confirmed by clinical staff * s not receiving moud through ongoing formal addiction treatment or pain management at the time of index ed visit * is willing to receive either standard ed care or enhanced ed care in edou depending on random assignment * presents to the ed during study screening hours exclusion criteria: * unwilling or unable to provide written/electronic informed consent/hipaa authorization for research procedures, including research visits at baseline and day 30 and day 90, and/or consent for the release of health records and data matching for a period of 2 years following enrollment and 1 year prior to enrollment. * currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or that could prevent participation in the study * presents from a medical-based extended care facility (e.g., skilled nursing facility) * previous participation in the current study * inadequate locator information (unable or unwilling to provide one unique mean of contact). * has acute, severe medical, psychiatric, or concurrent substance use problem or meets other criteria that would exclude the patient (clinically) from placement in edou according to edou placement clinical protocols.
goal-orientated therapy of perioperative disturbance in hemostasis in cardiac surgery

Conditions: Coronary Artery Bypass Graft Triple Vessel; Blood Coagulation Disorders

Summary: aim of this study is to investigate whether patients preoperatively treated with acetylsalicylic acid and/or clopidogrel have fewer perioperative bleeding and lower amounts of blood substitution when managed by rotem (whole blood coagulation analyzer) and multiplate (thrombocyte function analyzer).


Eligibility criteria:
inclusion criteria: * written consent exclusion criteria: * no written consent

Keywords: hemostasis monitoring perioperative blood loss
microvascular function in patients undergoing transcatheter aortic valve implant (tavi) for severe symptomatic aortic stenosis: association with myocardial fibrosis

Conditions: Severe Symptomatic Aortic Stenosis

Summary: microvascular function in patients undergoing transcatheter aortic valve implant (tavi) for severe symptomatic aortic stenosis: association with myocardial fibrosis

severe symptomatic aortic stenosis is commonly encountered in clinical practice, affecting close to 5% of individuals older than 65 years of age, and carries a dismal prognosis if left untreated.(1,2) chronically increased left ventricular afterload triggers a compensatory myocardial response, ultimately leading to ventricular hypertrophy, aimed at reducing chronically increased wall tension an restore cardiac performance.(3) hypertrophy ultimately results in maladaptive changes and ultimately leads to heart failure and eventually increased risk of cardiac mortality. myocardial fibrosis and altered myocardial perfusion appear to play a role in progressive cardiac decompensation.

Eligibility criteria:
inclusion criteria: • all patients referred to irccs ospedale san raffaele who are candidates to receive a tavi implant for severe, symptomatic aortic stenosis under current appropriateness criteria and clinical practice guidelines will be considered eligible to take part in the study exclusion criteria: * age \<18 years * inability to express informed consent to take part in the present study. * pregnancy or lactation * pre-existing known disease determining a prognosis quo ad vitam shorter than the follow up of the present study * significant chronic kidney disease (estimated glomerular filtration rate \<30 ml/min) * known significant epicardial coronary artery stenosis * known contraindication to adenosine administration: * known allergic reactions * second or third degree atrioventricular block before the procedure (in absence of a functional permanent pacemaker) * long qt syndrome * unstable angina * severe hypotension * acutely decompensated heart failure * chronic obstructive pulmonary disease with bronchospasm * concomitant use of dypiridamole
impact of systematic nursing orientations in the reduction of predicted cardiovascular risk in patients with coronary artery disease.

Conditions: Coronary Heart Disease

Summary: evaluate the impact of systematic nursing orientations in the reduction of predicted cardiovascular risk in patients with coronary artery disease during four nursing visits for a 1-year period and compare to a group of patients submitted to conventional treatment.

assess 184 (two groups) patients during four nursing visits for a 1-year period and compare to a group of patients submitted to conventional treatment. we will evaluate the impact of systematic nursing orientations in the reduction of predicted cardiovascular risk in patients with coronary artery disease.

Eligibility criteria:
inclusion criteria: * patients of both sexes; * aged 18 years or older; * diagnosed with acs (unstable angina and acute myocardial infarction with st segment elevation and without st segment elevation) with cad diagnosed by cardiac catheterization or electrocardiogram; * patients have to agree to participate by signing a consent term exclusion criteria: * patients with cognitive deficits; * neurological sequelae; * who are not able to come for visits, or who do not consent to participate in the study.

Keywords: nursing education cardiovascular risk factors coronary heart disease